February 19, 2019 / 6:21 AM / 7 months ago

BRIEF-Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

Feb 19 (Reuters) - Basilea Pharmaceutica AG:

* BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018

* FY TOTAL REVENUE INCREASED 31% TO CHF 133 MILLION

* FY REVENUE FROM CRESEMBA(®) AND ZEVTERA(®) INCREASED 56% TO CHF 82 MILLION

* YEAR-END CASH POSITION OF CHF 223 MILLION

* OPERATING LOSS IN 2018 AMOUNTED TO CHF 24.1 MILLION (2017: CHF 17.1 MILLION)

* ANTICIPATES 2019 CONTINUED STRONG REVENUE GROWTH FROM CRESEMBA AND ZEVTERA TO CHF 100-110 MILLION (+22-34% Y-ON-Y)

* FY NET LOSS CHF 31.4 MILLION VERSUS LOSS CHF 19.4 MILLION YEAR AGO

* 2019 TOTAL OPERATING EXPENSES ARE EXPECTED TO REMAIN AT APPROXIMATELY SAME LEVEL AS 2018,

* SEES FY 2019 OPERATING LOSS OF CHF 20-30 MILLION FOR 2019

* SEES 2019 TOTAL REVENUES TO AMOUNT TO CHF 128-138 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below